Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Call for Independent Scientific Experts to Join EMA’s Pharmacovigilance Risk Assessment Committee

Expressions of interest to be submitted to European Commission by 30 September 2017
20 Jul 2017
Bioethics, legal and economic issues

The Health and Safety Directorate-General of the European Commission has published a call for expressions of interest to join the European Medicines Agency’s (EMA’s) Pharmacovigilance Risk Assessment Committee (PRAC) as independent scientific experts.

This is an opportunity for specialists in pharmacovigilance to be part of one of the most advanced systems for the supervision of medicines and to make sure that medicines for patients in Europe are safe and effective. Appointees can make a real difference to the health of millions of patients in Europe.

This call is intended to select candidates to replace the independent experts currently serving on the Committee. Appointments will be made for a period of three years, which may be prolonged once and thereafter renewed, starting 2 July 2018. The PRAC’s current independent experts may reapply.

Expressions of interest should be submitted to the European Commission no later than 30 September 2017. Interested persons must complete both the application form and the form on declaration of interests, which can be downloaded from the website of the European Commission.

The independent scientific experts will be selected by the European Commission for their expertise. They are expected to attend the meetings of the PRAC, which meets each month, and to contribute to the Committee’s work by actively participating in PRAC’s scientific discussions, examining and commenting on documents. Working for the Committee will also involve some preparatory work before every session.

The PRAC has a key function for the assessment and monitoring of the safety of human medicines. The PRAC’s mandate covers all aspects of the risk management of the use of medicines including the detection, assessment, minimisation and communication relating to the risk of adverse reactions.

The Committee is composed of one member and one alternate appointed by each Member State, six scientific expert members appointed by the European Commission, one member and alternate representing healthcare professionals and one member and alternate representing patient organisations. The six scientific experts are expected to complement and further strengthen the expertise provided by the Member States' appointees and the patient organisations' and healthcare professionals' representatives.

Last update: 20 Jul 2017

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.